On the other hand, while the higher count of FoxP3-positive tumor cells predicts better survival in gastric and prostate cancers [24,28,29], in melanoma and NSCLC, high expression was associated with an unfavorable clinical prognosis, leading to shorter overall survival and recurrence-free survival [30,31]. This evidence concerns the gene FOXP3 and prostate carcinoma.